Ipca Laboratories Limited Bombay S.E.

Equities

IPCALAB

INE571A01038

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:46 2024-04-16 am EDT 5-day change 1st Jan Change
1,342 INR +1.10% Intraday chart for Ipca Laboratories Limited +1.42% +20.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director CI
Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director CI
Ipca Laboratories Licenses Anti-Cancer Biosimilar Technology to Omexa Formulary MT
Ipca Laboratories Limited Enters into A Technology Transfer Agreement with Omexa Formulary Pvt. Ltd CI
Nomura Adjusts IPCA Laboratories Price Target to INR1,308 From INR1,113, Keeps at Buy MT
Transcript : Ipca Laboratories Limited, Q3 2024 Earnings Call, Feb 15, 2024
Ipca Laboratories Limited Announces Appointment of Kamal Kishore Seth as the Lead Independent Director CI
Ipca Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Ipca Laboratories Limited, Q2 2024 Earnings Call, Nov 10, 2023
Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2023-24 CI
Ipca Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Ipca Laboratories' Pithampur Plant Classified as VAI by US FDA MT
Nomura Upgrades Ipca Laboratories to Buy From Neutral, Adjusts Price Target to INR1,133 From INR942 MT
INDIA STOCKS-Indian shares slide on Mideast jitters; ICICI Bank up on earnings beat RE
Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President ­ R&D (Formulations) CI
Ipca Laboratories Limited completed the acquisition of 19.29% stake in Unichem Laboratories Limited for INR 6 billion. CI
Ipca Laboratories' Piparia Manufacturing Plant in India Gets VAI Classification from US FDA MT
Nomura Adjusts IPCA Laboratories’ Price Target to INR942 From INR866, Keeps at Neutral MT
Transcript : Ipca Laboratories Limited, Q1 2024 Earnings Call, Aug 11, 2023
Ipca Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Ipca Laboratories Acquires 33% Stake in Unichem for INR9.45 Billion MT
Nomura Adjusts IPCA Laboratories’ Price Target to INR866 From INR911, Keeps at Neutral MT
Ipca Laboratories' Indore, India Unit Gets Eight Observations from US FDA Following Inspection MT
Indian shares set for muted start to week after Russia turmoil RE
Ipca Laboratories Gets 11 US FDA Observations from Inspection of APIs Manufacturing Unit in Ratlam, India MT
Chart Ipca Laboratories Limited
More charts
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
1,328 INR
Average target price
1,154 INR
Spread / Average Target
-13.10%
Consensus
  1. Stock Market
  2. Equities
  3. IPCALAB Stock
  4. IPCALAB Stock
  5. News Ipca Laboratories Limited
  6. Ipca Laboratories Acquires Minority Stake in Lyka Labs for Over $13 Million